← All trials
NCT03782467
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2019
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 53
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alligator Bioscience ABLead sponsor
- Karolinska InstituteOverall official - principal investigator
- Alligator Bioscience ABStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.